CMS Measure ID/CMS QCDR ID: CAP 37

Measure Title: Cancer Protocol for Gynecologic and Genitourinary Carcinomas: Carcinoma of the Endometrium, Prostate, and of Renal Tubular Origin

Measure Specifications

Measure Description	Percentage of all eligible pathology reports for specimens of carcinoma of the endometrium, prostate and renal tubular origin in which the required data elements of the gynecologic and genitourinary Cancer Protocols are recorded **AND** meet the maximum 4 business day turnaround time (TAT) requirement (Report Date – Accession Date ≤ 4 business days). INSTRUCTIONS: This measure has two performance rates that contribute to the overall performance score: 1. Percent of cases for which specified data elements for all cancer protocols are recorded. 2. Percent of cases that meet the maximum 4 business day turnaround time. The overall performance score submitted is a weighted average of: (Performance rate 1 x 70%)+(Performance rate 2 x 30%)
Denominator Statement	All final pathology reports for eligible specimens of carcinoma of the endometrium, prostate, and renal tubular origin that require the use of a CAP Cancer Protocol. CPT®[1]:88307, 88309 **AND** Any of the ICD10: • C61: malignant neoplasm of prostate • C64: malignant neoplasm of kidney, except renal pelvis • C64.1: malignant neoplasm of right kidney, except renal pelvis • C64.2: malignant neoplasm of left kidney, except renal pelvis • C64.9: malignant neoplasm of unspecified kidney, except renal pelvis • C54.0: malignant neoplasm of isthmus uteri • C54.1: malignant neoplasm of endometrium • C54.3: malignant neoplasm of fundus uteri • C54.8: malignant neoplasm of overlapping sites of corpus uteri • C54.9: malignant neoplasm of corpus uteri, unspecified • The denominator must be met between 01/01/2021 and 12/26/2021. This is to provide sufficient time for the performance of the numerator to be met within the performance period.
Denominator Exclusions	Biopsy procedures Cytology procedures Lymphomas

[1] CPT copyright: 2020 American Medical Association. All rights reserved.

	Sarcomas Resection specimens with no residual tumors Carcinomas arising in the uterine cervix Metastatic malignancy to one of these organs
Denominator Exceptions	Cases requiring intradepartmental or extra-departmental consultation

Numerator Statement	All eligible cases where the following required elements found in the current CAP Cancer Protocol are recorded:
	• Procedure
	• Histologic Grade
	• Histologic Type
	• Margin status
	• Lymphovascular invasion (endometrial and renal tubular carcinoma only)
	• Regional Lymph Nodes*
	  o Number of Nodes Examined
	  o Number of Nodes Involved
	• Pathologic Stage Classification: AJCC 8th Edition
	  o TNM Descriptors
	  o Primary Tumor (pT)
	  o Regional Lymph Nodes (pN)*
	  o Distant Metastases (pM)*
	• Myometrial Invasion (endometrial carcinoma only)
	• Uterine Serosa Involvement (endometrial carcinoma only)
	• Cervical Stroma Involvement (endometrial carcinoma only)
	• Extraprostatic extension (prostate carcinoma only)
	• Urinary Bladder Neck Invasion (prostate carcinoma only)
	• Seminal Vesicle Invasion (prostate carcinoma only)
	• Treatment Effect (prostate carcinoma only)
	• Specimen Laterality (renal tubular carcinoma only)
	• Tumor Extension (renal tubular carcinoma only)
	• Tumor Size (renal tubular carcinoma only)
	• Tumor Focality (renal tubular carcinoma only)
	• Tumor Necrosis (renal tubular carcinoma only)
	• Sarcomatoid Features (renal tubular carcinoma only)
	• Rhabdoid Features (renal tubular carcinoma only)
	
	* Required only if appropriate tissue/sample is present, can be omitted if no lymph nodes/distant metastases are provided
	
	AND
	Final pathology report in the laboratory/hospital information system with result verified by the pathologist and available to the requesting physician(s) within 4 business days.

Numerator Exclusions	None
Guidance	INSTRUCTIONS: This measure has two performance rates that contribute to the overall performance score: 1. Percent of cases for which specified data elements for all cancer protocols are recorded. 2. Percent of cases that meet the maximum 3 business day turnaround time. The overall performance score submitted is a weighted average of: (Performance rate 1 x 70%)+(Performance rate 2 x 30%) Denominator definitions: Eligible uterine resection cases include: • Total Hysterectomy • Supracervical Hysterectomy Radical Hysterectomy Eligible kidney resection cases include: • Partial Nephrectomy • Total Nephrectomy • Radical Nephrectomy Eligible prostate resection cases include: • Radical prostatectomy The numerator of Rate 1 is defined as cases of carcinoma of the endometrium or renal tubular origin for which all required data elements of the Cancer Protocol are included. If a case does not include one of the listed data elements, it may not be included in the Numerator for Rate 1 but may be included in the Numerator of Rate 2 if the required turnaround time is met. Numerator definitions for Rate 2: 1. Turnaround Time (TAT): The day the specimen is accessioned in the lab to the day the final report is signed out. Business days counted only. 2. Accession Date: The date recorded in the laboratory/hospital information system that documents when a specimen was received by the laboratory. 3. Report Date: The date recorded in the laboratory/hospital information system that documents when a result is verified and reported by the laboratory and is available to the requesting physician(s) (signed out). 4. Signed Out: The pathology report with a final diagnosis is released.
Measure Information	
NQS Domain	Communication and Care Coordination
Meaningful Measures Area(s)	Transfer of Health Information and Interoperability

Meaningful Measure Rationale	The CAP cancer protocols have been thoroughly researched and have been determined to contain all the elements that a clinician would need to appropriately treat a patient with a malignant disease. Therefore, utilizing all the required elements found in a CAP protocol for malignant cases should be the very definition of a high-quality report and serve as a measure of pathologist performance. An accurate and complete diagnosis as would be found in a high-quality pathology report with the CAP cancer template is crucial to successful patient treatment and outcomes. The cancer protocols standardize the collection and reporting of all cancer patient data, facilitates communication between pathologists, clinicians and cancer registrars, and improves and supports information exchange and data interoperability (1). Turnaround time (TAT) is an indicator of efficiency in anatomic pathology and may affect coordination of patient care. Timely pathology reports are one of the most important tools physicians use to adequately manage the quality and safety of patient care. The implication of surgical pathology report delay, as shown in research evidence, is that prolonged turnaround time plays a major role in disease complications, including raising morbidity and mortality rates. Therefore, verifying pathology reports in an appropriate timeframe helps healthcare practitioners with timely diagnosis and more effective treatment planning (2-4). 1. Krishnamurti, U, et. Al. CAP cancer protocols and pathology reports. Endometrium 4.1.0.2 (February 2020). https://documents.cap.org/protocols/cp-femalereproductive-endometrium-20-4102.pdf 2. Alshieban S. and Al-Surimi K. Reducing turnaround time of surgical pathology reports in pathology and laboratory medicine departments. BMJ Qual Improv Rep. 2015 Nov 24;4(1). pii: u209223.w3773. doi: 10.1136/bmjquality.u209223.w3773. eCollection 2015. 3. Volmar, KE et al. Turnaround Time for Large or Complex Specimens in Surgical Pathology: A College of American Pathologists Q-Probes Study of 56 Institutions. Archives of pathology & laboratory medicine. 139. 171-7. 10.5858/arpa.2013-0671-CP. 2015. 4. Patel, S. et al. Factors that impact turnaround time of surgical pathology specimens in an academic institution. Hum Pathol. 2012 Sep;43(9):1501-5. doi: 10.1016/j.humpath.2011.11.010. Epub 2012 Mar 8.
Measure Type	Process
Data Source	Laboratory Information System; CAP cancer protocols; and pathology reports
Summary of Performance Gap Evidence	A CAP Q-Probes study demonstrated that about 30% of cancer reports do not have all the scientifically validated elements required by the ACS CoC[1]. More recent studies have indicated that even among users of CAP Cancer Protocols, significant variability exists in rates of protocol completion, particularly dependent on the method of data capture (electronic cancer checklists versus printed paper forms versus web-based methods)[2]. The CAP cancer protocols have been thoroughly researched and have been

	determined to contain all the elements that a clinician would need to appropriately treat a patient with a malignant disease. Therefore, utilizing all the required elements found in a CAP protocol for malignant cases should be the very definition of a high-quality report and serve as a measure of pathologist performance. With respect to synoptic reports of gynecologic and genitourinary cancers specifically, results from the College of American Pathologists (CAP) Pathologists' Quality Registry show significant gaps in performance. The average performance rate for a measure covering cancer protocol of endometrial carcinoma was 48.3% with a standard deviation of 44.8 percentage points. The average performance rate for a measure covering cancer protocol of carcinoma of renal tubular origin was 66.8% with a standard deviation of 30.6 percentage points. Data is from all cases entered in 2019, totaling 1704 for endometrial cancer and 941 for carcinoma of renal tubular origin. 1. Michael O. Idowu, MD; Leonas G. Bekeris, MD; Stephen Raab, MD; Stephen G. Ruby, MD, MBA; Raouf E. Nakhleh, MD. Adequacy of Surgical Pathology Reporting of Cancer A College of American Pathologists Q-Probes Study of 86 Institutions Arch Pathol Lab Med. 2010;134:969–974. 2. Megan A Renshaw, Scott A Renshaw, Mercy Mena-Allauca, Patricia P Carrion, Xiaorong Mei, Arniris Narciandi, Edwin W Gould, Andrew A Renshaw. Performance of a web-based method for generating synoptic reports. J Pathology Informatics. 2017; 8:13.
Measure Owner	College of American Pathologists
NQF ID	N/A
Number of Performance Rates	1
Overall Performance Rate	1st Performance Rate
High-priority	Yes
Improvement Notation	Inverse Measure: No **Proportional Measure: Yes (Higher score indicates better quality)** Continuous Variable Measure: No Ratio Measure: No Risk-adjusted: No
Care Setting and Specialty	Care Setting: Other—Laboratories; Telehealth not applicable Specialty: Pathology

Current Clinical Guideline the Measure is Derived From	Guideline: None. Cancer Protocol: Srigley, J, et. Al. CAP cancer protocols and pathology reports. Kidney v4.0.2.0 (February 2020). https://documents.cap.org/protocols/cp-urinary-kidney-resection-20-4020.pdf Krishnamurti, U, et. Al. CAP cancer protocols and pathology reports. Endometrium 4.1.0.2 (February 2020). https://documents.cap.org/protocols/cp-femalereproductive-endometrium-20-4102.pdf Gladell, PP et al. CAP Cancer protocols and pathology reports. Prostate v4.1.0.1 (March 2020) https://documents.cap.org/protocols/cp-malegenital-prostate-radicalprostatectomy-20-4101.pdf

Measure Flow